About the Company
We do not have any company description for Inhibrx Biosciences, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Inhibrx Biosciences, Inc.
Inhibrx, Inc. Announces Updated When-Issued Trading Date for ...
Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its ...
Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial Results
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter ...
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
--Inhibrx Biosciences, Inc. today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. to Sanofi S.A. and the Former Parent ...
Inhibrx Biosciences, Inc.: Inhibrx Biosciences Announces Preliminary ...
Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx ...
Inhibrx Biosciences, Inc. (INBX) - Yahoo Finance
Get the detailed quarterly/annual income statement for Inhibrx Biosciences, Inc. (INBX). Find out the revenue, expenses and profit or loss over the last fiscal year.
Inhibrx Biosciences Announces Departure of CSO and ... - Morningstar
Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx ...
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial ...
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer Jan. 21, 2025 5:01 PM ET Inhibrx Biosciences, Inc. (INBX) ...
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it ...
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx ...
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today ...
Similar Companies
Loading the latest forecasts...